IDEXX Laboratories, Inc. (BMV:IDXX)
Mexico · Delayed Price · Currency is MXN | Market Cap | 757.17B -1.3% |
| Revenue (ttm) | 80.15B +13.1% |
| Net Income | 19.74B +22.4% |
| EPS | 245.07 +25.7% |
| Shares Out | n/a |
| PE Ratio | 38.35 |
| Forward PE | 36.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 70 |
| Open | 9,197.48 |
| Previous Close | 9,197.48 |
| Day's Range | 9,197.48 - 9,197.48 |
| 52-Week Range | 9,109.15 - 14,130.00 |
| Beta | n/a |
| RSI | 33.32 |
| Earnings Date | May 5, 2026 |
About IDEXX Laboratories
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides com... [Read more]
Financial Performance
In 2025, IDEXX Laboratories's revenue was $4.30 billion, an increase of 10.42% compared to the previous year's $3.90 billion. Earnings were $1.06 billion, an increase of 19.33%.
Financial numbers in USD Financial StatementsNews
Idexx Laboratories announces SDMA to be built into Catalyst CLIPs
IDEXX Laboratories (IDXX) announced that SDMA, a renal biomarker, will be built into Catalyst CLIPs, making complete kidney function evaluation part of the most common point-of-care chemistry profiles...
IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX integrates SDMA into most common Catalyst chemistry profiles, enabling earlier detection of kidney disease through routine in‑clinic testing.
IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, wil...
IDEXX Laboratories Transcript: AGM 2026
The meeting featured a CEO transition, approval of all management proposals including board declassification and special meeting rights for 25% shareholders, and rejection of a shareholder proposal for a 10% threshold. No questions were raised during the Q&A.
Idexx Laboratories price target lowered to $660 from $790 at BofA
BofA lowered the firm’s price target on Idexx Laboratories (IDXX) to $660 from $790 and keeps a Neutral rating on the shares. The firm sees today’s Q1 beat as “demonstrating…
IDEXX Laboratories Earnings Call Transcript: Q1 2026
Q1 2026 saw 14% reported and 11% organic revenue growth, with strong gains in CAG Diagnostics, premium instrument placements, and international markets. Full-year guidance was raised for revenue, EPS, and operating margin, supported by innovation and robust customer retention.
IDEXX Laboratories Earnings release: Q1 2026
IDEXX Laboratories released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
IDEXX Laboratories Slides: Q1 2026
IDEXX Laboratories has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
IDEXX Laboratories Quarterly report: Q1 2026
IDEXX Laboratories has published its Q1 2026 quarterly earnings report on May 5, 2026.
Idexx Laboratories reports Q1 EPS $3.47, consensus $3.41
Reports Q1 revenue $1.14B, consensus $1.11B. “Excellent commercial execution delivered exceptional first quarter results and positions IDEXX for continued strength through 2026,” said Jay Mazelsky, Pr...
Idexx Laboratories raises FY26 EPS view to $14.45-$14.90 from $14.29-$14.80
FY26 consensus $14.51. Raises FY26 reported revenue growth view to 8.6%-10.6% and CAG Diagnostics recurring revenue reported growth of 9.6%-11.6%, with projected 2026 organic revenue growth of 7.7%-9....
IDEXX Laboratories Announces First Quarter Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company repor...
Idexx Laboratories price target lowered to $640 from $730 at UBS
UBS analyst Andrea Alfonso lowered the firm’s price target on Idexx Laboratories (IDXX) to $640 from $730 and keeps a Neutral rating on the shares. The Q1 earnings outlook is…
University of New England launches new Institute of Public and Planetary Health in honor of philanthropist and IDEXX Founder David Evans Shaw
A $5 million gift from the storied entrepreneur, activist, and impact investor will advance the University of New England's work at the intersection of environmental and human health while boosting Ma...
Idexx Laboratories initiated with a Neutral at Citi
Citi analyst Daniel Grosslight initiated coverage of Idexx Laboratories (IDXX) with a Neutral rating and $650 price target The firm launched the animal health and dental sectors with a “cautiously…
IDEXX Laboratories to Release 2026 First Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 first quarter financial results for Tues...
Idexx Laboratories announces Idexx Cancer Dx Panel availability in the UK
Idexx Laboratories (IDXX) announced the availability of the Idexx Cancer Dx Panel in the United Kingdom, beginning with early detection of lymphoma in at-risk dogs.
IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Cancer Dx Panel with canine lymphoma detection helps clinicians investigate sooner and plan next steps with confidence.
Idexx Laboratories price target lowered to $675 from $775 at Stifel
Stifel analyst Jonathan Block lowered the firm’s price target on Idexx Laboratories (IDXX) to $675 from $775 and keeps a Buy rating on the shares. The firm continues to view…
IDEXX Laboratories Proxy statement: Proxy filing
IDEXX Laboratories filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
IDEXX Laboratories Proxy statement: Proxy filing
IDEXX Laboratories filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
Idexx Laboratories management to meet with Piper Sandler
Meeting to be held in Boston on April 1 hosted by Piper Sandler.
IDEXX Laboratories Proxy statement: Proxy Filing
IDEXX Laboratories filed a proxy statement on March 13, 2026, providing details for shareholder voting and corporate governance matters.
IDEXX Laboratories Transcript: 47th Annual Raymond James Institutional Investor Conference
A robust innovation-driven strategy is fueling double-digit growth in veterinary diagnostics, supported by expanding international markets, increased pet longevity, and accelerated investment in new platforms and oncology solutions. Long-term targets include 10%+ revenue growth and 15%+ EPS growth.
IDEXX Laboratories Slides: 47th Annual Raymond James Institutional Investor Conference
IDEXX Laboratories has posted slides in relation to its latest quarterly earnings report, which was published on March 2, 2026.